Logo
Menu
  • Who We Are
  • How We Invest
  • Our Portfolio
    • Abzena
    • Ixlayer
    • Kiniciti
    • PathAI
  • Blog
  • Careers
  • Contact
Kiniciti, Ncardia, and the Future of Cell & Gene Therapy

Kiniciti, Ncardia, and the Future of Cell & Gene Therapy

by Biospring | Apr 26, 2022 | Advanced Therapy, Cell Therapy, CGT, Gene Therapy, Geoffrey Glass, IPSC, Kiniciti, NCardia

In November 2021, we were pleased to announce our investment in Kiniciti, a Cell & Gene Therapy (“CGT”) aggregator. Later in November, Kiniciti announced its first strategic partnership with Ncardia, a leader in developing stem cell-based solutions for...
Our investment in Kiniciti

Our investment in Kiniciti

by Biospring | Apr 26, 2022 | Cell and Gene Therapy, Cell Therapy, CGT, Gene Therapy, Kiniciti

We’re pleased to announce our investment in Kiniciti, a Cell and Gene Therapy (“CGT”) aggregator. We’ve had the pleasure of working with Kiniciti over the past year to identify opportunities in the cell and gene therapy market. Biospring’s...

Recent Posts

  • Biospring Partners Welcomes Industry Executives To Its Advisory Board
  • Biomanufacturing: A Growing Field
  • Interview with Zach Weinberg
  • Driving Drug Development with Data Science
  • Proteomics 101

Recent Comments

No comments to show.

Newsletter

Thank you for subscribing!

Subscribe